- Home
- VSTM vs YMAB Comparison
VSTM vs YMAB Comparison
Compare VSTM & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VSTM
- YMAB
- Stock Information
- Founded
- VSTM 2010
- YMAB 2015
- Country
- VSTM United States
- YMAB United States
- Employees
- VSTM N/A
- YMAB N/A
- Industry
- VSTM Biotechnology: Pharmaceutical Preparations
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- VSTM Health Care
- YMAB Health Care
- Exchange
- VSTM Nasdaq
- YMAB Nasdaq
- Market Cap
- VSTM 263.5M
- YMAB 270.5M
- IPO Year
- VSTM 2012
- YMAB 2018
- Fundamental
- Price
- VSTM $5.68
- YMAB $5.72
- Analyst Decision
- VSTM Strong Buy
- YMAB Strong Buy
- Analyst Count
- VSTM 8
- YMAB 10
- Target Price
- VSTM $12.67
- YMAB $21.10
- AVG Volume (30 Days)
- VSTM 837.6K
- YMAB 542.6K
- Earning Date
- VSTM 03-13-2025
- YMAB 03-04-2025
- Dividend Yield
- VSTM N/A
- YMAB N/A
- EPS Growth
- VSTM N/A
- YMAB N/A
- EPS
- VSTM N/A
- YMAB N/A
- Revenue
- VSTM $10,000,000.00
- YMAB $84,553,000.00
- Revenue This Year
- VSTM N/A
- YMAB $6.41
- Revenue Next Year
- VSTM $117.91
- YMAB $18.15
- P/E Ratio
- VSTM N/A
- YMAB N/A
- Revenue Growth
- VSTM N/A
- YMAB N/A
- 52 Week Low
- VSTM $2.10
- YMAB $5.60
- 52 Week High
- VSTM $13.82
- YMAB $20.90
- Technical
- Relative Strength Index (RSI)
- VSTM 49.67
- YMAB 35.08
- Support Level
- VSTM $5.48
- YMAB $5.60
- Resistance Level
- VSTM $6.17
- YMAB $6.57
- Average True Range (ATR)
- VSTM 0.32
- YMAB 0.38
- MACD
- VSTM -0.07
- YMAB 0.10
- Stochastic Oscillator
- VSTM 35.53
- YMAB 11.43
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.